D.E. Shaw & Co
KYTX icon

D.E. Shaw & Co’s Kyverna Therapeutics KYTX Stock Holding History

D.E. Shaw & Co’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.18M Sell
469,346
-252,235
-35% -$2.24M ﹤0.01% 2556
2026
Q1 		$6.23M Buy
721,581
+203,069
+39% +$1.69M ﹤0.01% 2015
2025
Q4 		$4.87M Buy
+518,512
New +$3.85M ﹤0.01% 2318

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

D.E. Shaw & Co's KYTX Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Kyverna Therapeutics (KYTX) stake by 35% in Q2 2026, selling an estimated $2.24M and leaving 469,346 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2556.

D.E. Shaw & Co first reported a position in KYTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.23M in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • D.E. Shaw & Co held 469,346 shares of Kyverna Therapeutics worth $4.18M as of Q2 2026.
  • D.E. Shaw & Co sold 252,235 Kyverna Therapeutics shares in Q2 2026, an estimated $2.24M.
  • Kyverna Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2556 holding.
  • D.E. Shaw & Co first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • D.E. Shaw & Co's Kyverna Therapeutics position peaked at $6.23M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.